{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 45,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "Includes structural biology diagrams of BCR-ABL protein domains and a table comparing binding conformations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/26",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.205,
        "x": 0.69,
        "y": 0.395
      },
      "kind": "callout",
      "text": "ATP Competitive BCR-ABL Inhibitors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a82d924-d46e-4e1f-9d4f-529d1ebb26f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.7,
        "x": 0.15,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Y=Tyrosine; NLS=Nuclear Localization Signal; SH1=Src Homology 1 Domain; SH2=Src Homology 2 Domain; SH3=Src Homology 3 Domain; DB=DNA-Binding Region; AB=Actin-Binding Region; BCR=Breakpoint cluster region",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dbfdb76-18c6-4fbe-b51f-555ee8a06eb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.75,
        "x": 0.13,
        "y": 0.315
      },
      "kind": "image",
      "text": "Structural diagram of BCR-ABL protein domains",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa5e59a2-ba0e-41d5-abb4-5d9f575476b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.215,
        "x": 0.357,
        "y": 0.175
      },
      "kind": "table",
      "text": "ATP-Binding Site table comparing ELVN-001, Bosutinib, Dasatinib, Imatinib, Nilotinib, and Ponatinib",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4da9b26b-178e-46e5-81c0-b120e45acf79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.215,
        "x": 0.307,
        "y": 0.785
      },
      "kind": "table",
      "text": "Myristoyl Pocket table for Asciminib",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0ecb012-c4a0-4e51-9893-948386ee58c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELVN-001 is a Selective Active Site, Active Form Inhibitor of BCR-ABL",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c16faea2-2469-412f-a65a-cce5b9af3021",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "f2f5d6c7-cd0e-48bd-9598-6af0939e4d26",
      "evidence": "table/data comparing ELVN-001 with other compounds",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 10,
      "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500",
      "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.",
      "position": 0,
      "objective": "What are the consequences of not having better treatment options for CML?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}